Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Efficacy Study of Primaquine and Methylene Blue

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Glucose-6-phosphate dehydrogenase (G6PD) normal defined by CareStart™ G6PD rapid diagnostic test (RDT) or the OSMMR2000 G6PD semi-qualitative test~* Absence of symptomatic falciparum malaria, defined by fever upon enrollment~* Presence of P. falciparum gametocytes on thick blood film at a density \>30 gametocytes/µL (i.e. ≥2 gametocytes recorded in the thick film against 500 white blood cells)~* No allergies to study drugs~* No self-reported use of antimalarial drugs over the past 7 days (as reported by the participant)~* Hemoglobin ≥ 10 g/dL~* Individuals weighing \<80 kg~* No evidence of severe or chronic disease~* Written, informed consent~Exclusion Criteria:~* Age \< 5 years or \> 50 years~* Female gender~* Blood thick film negative for sexual stages of malaria~* Previous reaction to study drugs/known allergy to study drugs~* Signs of severe malaria, including hyperparasitemia, defined as asexual parasitemia \> 100,000 parasites / µL)~* Signs of acute or chronic illness, including hepatitis~* Use of other medications (with the exception of paracetamol and/or aspirin)~* Consent not given

- Gender: MALE
- Minimum Age: 5 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- SP-AQ only (Type: ACTIVE_COMPARATOR): Subjects will receive sulphadoxine-pyrimethamine (SP) as single dose and administered in combination with amodiaquine (AQ), which will be given once daily for 3 days.
- SP-AQ plus PQ (Type: EXPERIMENTAL): Participants in this arm will receive SP-AQ in combination with a single low dose of primaquine at the World Health Organization (WHO) recommended dose of 0.25 mg/kg.
- DP only (Type: ACTIVE_COMPARATOR): Participants in this arm will be treated with dihydroartemisinin-piperaquine (DP), which will be administered once a day for three days.
- DP plus MB (Type: EXPERIMENTAL): Study participants in this arm will receive DP as described above combined with once-daily methylene blue (MB) for 3 days, at 15 mg/kg/day (45 mg/kg total over 3 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).